U.S. markets closed

Talis Biomedical Corporation (TLIS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.17-0.79 (-6.10%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close12.96
Open12.76
Bid11.00 x 800
Ask14.00 x 900
Day's Range12.12 - 12.95
52 Week Range10.65 - 33.90
Volume72,299
Avg. Volume393,533
Market Cap312.01M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Talis Appoints Jeryl Hilleman to Board of Directors
    GlobeNewswire

    Talis Appoints Jeryl Hilleman to Board of Directors

    MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the appointment of Jeryl “Jeri” Hilleman to its Board of Directors. Ms. Hilleman will serve as Chair of the Audit Committee. “We welcome Jeri to our Board and look forward to benefitting from her public company leadership as a chief financial officer and corporate director at multiple life science companies,” said Brian Coe, Chief Executive Officer of Talis. “Jeri’s experience and guidance will be instrumental as we continue to scale our business in preparation for the commercial launch of Talis One™.” Ms. Hilleman brings over 20 years of executive leadership and financial experience to Talis. She currently serves as Chairman of the Board of Omada Health and is a Director of Novocure, SI-Bone and Minerva Neurosciences. Prior to her decision to focus on board responsibilities full time in 2020, Ms. Hilleman served as a Chief Financial Officer for more than 20 years at multiple public companies in the life science industry, including Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and Cytel. “Driven by the opportunity to help companies define growth strategies, I look forward to working with the Talis Board and leadership team in their efforts to transform diagnostic testing for infectious diseases at the point-of-care,” said Ms. Hilleman. Ms. Hilleman graduated from Brown University and earned an MBA from the Wharton School of the University of Pennsylvania. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute. About the Talis One PlatformThe Talis One platform is a compact, sample-to-answer, cloud-enabled, molecular diagnostic solution that, once authorized for marketing, could be rapidly deployed to distributed diagnostic settings in the United States and around the world to diagnose infectious diseases at the point-of-care. The Talis One assays are based on a highly optimized nucleic acid isothermal amplification chemistry to achieve test performance faster than traditional polymerase chain reaction (PCR) tests. The Talis One platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, elder care/assisted living facilities, and cancer treatment and dialysis centers. COVID-19 is the first infectious disease that the Talis One platform is designed to detect. Future infectious disease indications may include assays for other respiratory infections, such as influenza, as well as sexually transmitted infections (STIs) and other infections impacting women’s health. The Talis One platform, currently in development, is designed to be managed remotely, to send test results to a cloud database for secure transmission, storage and review, and to return results in approximately 25 minutes. About TalisTalis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio. Contact:Media & InvestorsEmily Faucetteefaucette@talisbio.com+1.415.595.9407

  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021

    Upgrades ScotiaBank upgraded the previous rating for Primo Water Corp (NYSE:PRMW) from Sector Perform to Outperform. Primo Water earned $0.14 in the fourth quarter, compared to $0.00 in the year-ago quarter. The stock has a 52-week-high of $17.85 and a 52-week-low of $6.33. At the end of the last trading period, Primo Water closed at $15.42. B of A Securities upgraded the previous rating for FirstEnergy Corp (NYSE:FE) from Neutral to Buy. FirstEnergy earned $0.32 in the fourth quarter, compared to $0.55 in the year-ago quarter. The current stock performance of FirstEnergy shows a 52-week-high of $46.69 and a 52-week-low of $22.85. Moreover, at the end of the last trading period, the closing price was at $33.36. According to Argus Research, the prior rating for BHP Group Ltd (NYSE:BHP) was changed from Hold to Buy. At the moment, the stock has a 52-week-high of $81.82 and a 52-week-low of $29.78. BHP Group closed at $75.79 at the end of the last trading period. DA Davidson upgraded the previous rating for NeoPhotonics Corp (NYSE:NPTN) from Neutral to Buy. In the fourth quarter, NeoPhotonics showed an EPS of $0.14, compared to $0.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of $14.14 and a 52-week-low of $4.65. NeoPhotonics closed at $8.43 at the end of the last trading period. According to Benchmark, the prior rating for Shift Technologies Inc (NASDAQ:SFT) was changed from Hold to Buy. Interestingly, in the fourth quarter, Shift Technologies's EPS was $0.07. The stock has a 52-week-high of $12.34 and a 52-week-low of $6.40. At the end of the last trading period, Shift Technologies closed at $7.68. New Street upgraded the previous rating for Tesla Inc (NASDAQ:TSLA) from Neutral to Buy. Tesla earned $0.80 in the fourth quarter, compared to $0.41 in the year-ago quarter. The current stock performance of Tesla shows a 52-week-high of $900.40 and a 52-week-low of $70.10. Moreover, at the end of the last trading period, the closing price was at $563.00. According to Goldman Sachs, the prior rating for Nomura Holdings Inc (NYSE:NMR) was changed from Neutral to Buy. In the third quarter, Nomura Holdings showed an EPS of $0.30, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $6.31 and a 52-week-low of $3.55. At the end of the last trading period, Nomura Holdings closed at $6.20. Johnson Rice upgraded the previous rating for Southwestern Energy Co (NYSE:SWN) from Hold to Buy. Southwestern Energy earned $0.18 in the fourth quarter, compared to $0.18 in the year-ago quarter. The current stock performance of Southwestern Energy shows a 52-week-high of $4.69 and a 52-week-low of $1.06. Moreover, at the end of the last trading period, the closing price was at $3.78. For XPeng Inc (NYSE:XPEV), Daiwa Capital upgraded the previous rating of Sell to Buy. In the fourth quarter, XPeng earned $0.15. The stock has a 52-week-high of $74.49 and a 52-week-low of $17.11. At the end of the last trading period, XPeng closed at $26.92. For Extended Stay America Inc (NASDAQ:STAY), Baird upgraded the previous rating of Neutral to Outperform. In the fourth quarter, Extended Stay America showed an EPS of $0.16, compared to $0.14 from the year-ago quarter. The stock has a 52-week-high of $17.01 and a 52-week-low of $5.35. At the end of the last trading period, Extended Stay America closed at $16.79. For Whiting Petroleum Corp (NYSE:WLL), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. For the fourth quarter, Whiting Petroleum had an EPS of $1.46, compared to year-ago quarter EPS of $0.22. The current stock performance of Whiting Petroleum shows a 52-week-high of $38.82 and a 52-week-low of $0.25. Moreover, at the end of the last trading period, the closing price was at $33.70. According to Wells Fargo, the prior rating for Antero Resources Corp (NYSE:AR) was changed from Underweight to Equal-Weight. Antero Resources earned $0.03 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of $10.30 and a 52-week-low of $0.64. Antero Resources closed at $9.72 at the end of the last trading period. According to Stifel, the prior rating for Camtek Ltd (NASDAQ:CAMT) was changed from Hold to Buy. For the fourth quarter, Camtek had an EPS of $0.21, compared to year-ago quarter EPS of $0.14. The current stock performance of Camtek shows a 52-week-high of $30.39 and a 52-week-low of $6.26. Moreover, at the end of the last trading period, the closing price was at $25.39. For Devon Energy Corp (NYSE:DVN), Johnson Rice upgraded the previous rating of Accumulate to Buy. In the fourth quarter, Devon Energy showed an EPS of $0.01, compared to $0.36 from the year-ago quarter. The current stock performance of Devon Energy shows a 52-week-high of $26.13 and a 52-week-low of $4.70. Moreover, at the end of the last trading period, the closing price was at $24.53. According to Johnson Rice, the prior rating for Callon Petroleum Co (NYSE:CPE) was changed from Hold to Accumulate. For the fourth quarter, Callon Petroleum had an EPS of $1.00, compared to year-ago quarter EPS of $0.23. At the moment, the stock has a 52-week-high of $40.98 and a 52-week-low of $0.38. Callon Petroleum closed at $36.90 at the end of the last trading period. According to Deutsche Bank, the prior rating for Pure Storage Inc (NYSE:PSTG) was changed from Hold to Buy. Pure Storage earned $0.13 in the fourth quarter, compared to $0.23 in the year-ago quarter. The stock has a 52-week-high of $29.53 and a 52-week-low of $7.93. At the end of the last trading period, Pure Storage closed at $19.37. See all analyst ratings upgrades. Downgrades Citigroup downgraded the previous rating for ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) from Buy to Neutral. ACADIA Pharmaceuticals earned $0.42 in the fourth quarter, compared to $0.34 in the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $58.72 and a 52-week-low of $30.02. Moreover, at the end of the last trading period, the closing price was at $45.78. According to Wolfe Research, the prior rating for PPL Corp (NYSE:PPL) was changed from Outperform to Peer Perform. In the fourth quarter, PPL showed an EPS of $0.59, compared to $0.57 from the year-ago quarter. The current stock performance of PPL shows a 52-week-high of $31.71 and a 52-week-low of $18.12. Moreover, at the end of the last trading period, the closing price was at $28.35. For TriState Capital Holdings Inc (NASDAQ:TSC), Wedbush downgraded the previous rating of Outperform to Neutral. In the fourth quarter, TriState Capital Holdings showed an EPS of $0.37, compared to $0.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $26.22 and a 52-week-low of $7.59. TriState Capital Holdings closed at $25.94 at the end of the last trading period. UBS downgraded the previous rating for NuStar Energy LP (NYSE:NS) from Buy to Neutral. In the fourth quarter, NuStar Energy showed an EPS of $0.13, compared to $0.40 from the year-ago quarter. The current stock performance of NuStar Energy shows a 52-week-high of $20.74 and a 52-week-low of $4.98. Moreover, at the end of the last trading period, the closing price was at $19.84. For AnaptysBio Inc (NASDAQ:ANAB), Wedbush downgraded the previous rating of Outperform to Neutral. For the fourth quarter, AnaptysBio had an EPS of $1.20, compared to year-ago quarter EPS of $0.75. The current stock performance of AnaptysBio shows a 52-week-high of $35.85 and a 52-week-low of $12.06. Moreover, at the end of the last trading period, the closing price was at $19.51. According to Bernstein, the prior rating for Kinder Morgan Inc (NYSE:KMI) was changed from Outperform to Market Perform. Kinder Morgan earned $0.27 in the fourth quarter, compared to $0.26 in the year-ago quarter. The stock has a 52-week-high of $19.44 and a 52-week-low of $9.42. At the end of the last trading period, Kinder Morgan closed at $16.21. According to Goldman Sachs, the prior rating for Tanger Factory Outlet Centers Inc (NYSE:SKT) was changed from Neutral to Sell. In the fourth quarter, Tanger Factory Outlet showed an EPS of $0.54, compared to $0.59 from the year-ago quarter. At the moment, the stock has a 52-week-high of $22.40 and a 52-week-low of $4.05. Tanger Factory Outlet closed at $17.13 at the end of the last trading period. B of A Securities downgraded the previous rating for Atmos Energy Corp (NYSE:ATO) from Buy to Neutral. In the first quarter, Atmos Energy showed an EPS of $1.71, compared to $1.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $111.67 and a 52-week-low of $77.92. Atmos Energy closed at $91.52 at the end of the last trading period. For ONE Gas Inc (NYSE:OGS), B of A Securities downgraded the previous rating of Neutral to Underperform. For the fourth quarter, ONE Gas had an EPS of $1.09, compared to year-ago quarter EPS of $0.96. The stock has a 52-week-high of $92.00 and a 52-week-low of $63.67. At the end of the last trading period, ONE Gas closed at $75.08. For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Raymond James downgraded the previous rating of Strong Buy to Outperform. In the fourth quarter, ACADIA Pharmaceuticals showed an EPS of $0.42, compared to $0.34 from the year-ago quarter. At the moment, the stock has a 52-week-high of $58.72 and a 52-week-low of $30.02. ACADIA Pharmaceuticals closed at $45.78 at the end of the last trading period. For Five Prime Therapeutics Inc (NASDAQ:FPRX), Guggenheim downgraded the previous rating of Buy to Neutral. In the third quarter, Five Prime Therapeutics showed an EPS of $0.74, compared to $1.03 from the year-ago quarter. The stock has a 52-week-high of $38.18 and a 52-week-low of $1.75. At the end of the last trading period, Five Prime Therapeutics closed at $37.76. For Bloomin Brands Inc (NASDAQ:BLMN), Deutsche Bank downgraded the previous rating of Buy to Hold. For the fourth quarter, Bloomin Brands had an EPS of $0.02, compared to year-ago quarter EPS of $0.32. The current stock performance of Bloomin Brands shows a 52-week-high of $27.97 and a 52-week-low of $4.54. Moreover, at the end of the last trading period, the closing price was at $27.21. Piper Sandler downgraded the previous rating for Cactus Inc (NYSE:WHD) from Overweight to Neutral. Cactus earned $0.08 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $39.07 and a 52-week-low of $8.16. At the end of the last trading period, Cactus closed at $38.67. Johnson Rice downgraded the previous rating for EOG Resources Inc (NYSE:EOG) from Buy to Accumulate. For the fourth quarter, EOG Resources had an EPS of $0.71, compared to year-ago quarter EPS of $1.35. At the moment, the stock has a 52-week-high of $75.80 and a 52-week-low of $27.00. EOG Resources closed at $74.48 at the end of the last trading period. For Cabot Oil & Gas Corp (NYSE:COG), Johnson Rice downgraded the previous rating of Buy to Hold. For the fourth quarter, Cabot Oil & Gas had an EPS of $0.26, compared to year-ago quarter EPS of $0.30. The current stock performance of Cabot Oil & Gas shows a 52-week-high of $22.67 and a 52-week-low of $13.16. Moreover, at the end of the last trading period, the closing price was at $19.10. Johnson Rice downgraded the previous rating for Pioneer Natural Resources Co (NYSE:PXD) from Buy to Hold. Pioneer Natural Resources earned $1.07 in the fourth quarter, compared to $2.36 in the year-ago quarter. At the moment, the stock has a 52-week-high of $165.57 and a 52-week-low of $48.62. Pioneer Natural Resources closed at $161.97 at the end of the last trading period. According to Wells Fargo, the prior rating for OGE Energy Corp (NYSE:OGE) was changed from Overweight to Equal-Weight. OGE Energy earned $0.27 in the fourth quarter, compared to $0.18 in the year-ago quarter. The current stock performance of OGE Energy shows a 52-week-high of $37.88 and a 52-week-low of $23.00. Moreover, at the end of the last trading period, the closing price was at $32.05. Wells Fargo downgraded the previous rating for Athene Holding Ltd (NYSE:ATH) from Overweight to Equal-Weight. In the fourth quarter, Athene Holding showed an EPS of $2.85, compared to $1.97 from the year-ago quarter. The current stock performance of Athene Holding shows a 52-week-high of $55.39 and a 52-week-low of $13.37. Moreover, at the end of the last trading period, the closing price was at $51.82. According to Morgan Stanley, the prior rating for Evertec Inc (NYSE:EVTC) was changed from Equal-Weight to Underweight. In the fourth quarter, Evertec showed an EPS of $0.59, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $42.35 and a 52-week-low of $18.21. At the end of the last trading period, Evertec closed at $37.60. According to Deutsche Bank, the prior rating for Stitch Fix Inc (NASDAQ:SFIX) was changed from Buy to Hold. For the second quarter, Stitch Fix had an EPS of $0.20, compared to year-ago quarter EPS of $0.11. The current stock performance of Stitch Fix shows a 52-week-high of $113.76 and a 52-week-low of $10.90. Moreover, at the end of the last trading period, the closing price was at $68.52. For Range Resources Corp (NYSE:RRC), Wells Fargo downgraded the previous rating of Overweight to Equal-Weight. Range Resources earned $0.02 in the fourth quarter, compared to $0.08 in the year-ago quarter. At the moment, the stock has a 52-week-high of $11.60 and a 52-week-low of $1.61. Range Resources closed at $10.18 at the end of the last trading period. For SM Energy Co (NYSE:SM), Wells Fargo downgraded the previous rating of Overweight to Equal-Weight. SM Energy earned $0.02 in the fourth quarter, compared to $0.04 in the year-ago quarter. The stock has a 52-week-high of $19.29 and a 52-week-low of $0.90. At the end of the last trading period, SM Energy closed at $16.41. Wells Fargo downgraded the previous rating for Oasis Petroleum Inc (NASDAQ:OAS) from Equal-Weight to Underweight. For the fourth quarter, Oasis Petroleum had an EPS of No EPS Value , compared to year-ago quarter EPS of $0.02. The current stock performance of Oasis Petroleum shows a 52-week-high of $61.17 and a 52-week-low of $0.15. Moreover, at the end of the last trading period, the closing price was at $59.27. Wells Fargo downgraded the previous rating for Matador Resources Co (NYSE:MTDR) from Overweight to Equal-Weight. Matador Resources earned $0.27 in the fourth quarter, compared to $0.39 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.43 and a 52-week-low of $1.11. Matador Resources closed at $25.18 at the end of the last trading period. See all analyst ratings downgrades. Initiations With a Buy rating, Citigroup initiated coverage on The Home Depot Inc (NYSE:HD). The price target seems to have been set at $288.00 for Home Depot. Home Depot earned $2.74 in the fourth quarter, compared to $2.28 in the year-ago quarter. The stock has a 52-week-high of $292.95 and a 52-week-low of $140.63. At the end of the last trading period, Home Depot closed at $259.39. With a Neutral rating, Citigroup initiated coverage on Chewy Inc (NYSE:CHWY). The price target seems to have been set at $95.00 for Chewy. For the third quarter, Chewy had an EPS of $0.08, compared to year-ago quarter EPS of $0.20. The stock has a 52-week-high of $120.00 and a 52-week-low of $20.62. At the end of the last trading period, Chewy closed at $76.26. Jefferies initiated coverage on loanDepot Inc (NYSE:LDI) with a Buy rating. The price target for loanDepot is set to $33.00. The current stock performance of loanDepot shows a 52-week-high of $39.85 and a 52-week-low of $14.00. Moreover, at the end of the last trading period, the closing price was at $19.14. Canaccord Genuity initiated coverage on Delcath Systems Inc (NASDAQ:DCTH) with a Buy rating. The price target for Delcath Systems is set to $24.00. In the third quarter, Delcath Systems showed an EPS of $1.16, compared to $0.32 from the year-ago quarter. At the moment, the stock has a 52-week-high of $25.18 and a 52-week-low of $6.06. Delcath Systems closed at $17.65 at the end of the last trading period. Jefferies initiated coverage on Rada Electronics Industries Ltd (NASDAQ:RADA) with a Buy rating. The price target for Rada Electronics Industri is set to $16.00. In the fourth quarter, Rada Electronics Industri showed an EPS of $0.06, compared to $0.01 from the year-ago quarter. At the moment, the stock has a 52-week-high of $14.80 and a 52-week-low of $2.05. Rada Electronics Industri closed at $11.81 at the end of the last trading period. Truist Securities initiated coverage on DHT Holdings Inc (NYSE:DHT) with a Buy rating. The price target for DHT Holdings is set to $15.00. DHT Holdings earned $0.04 in the fourth quarter, compared to $0.47 in the year-ago quarter. The current stock performance of DHT Holdings shows a 52-week-high of $8.68 and a 52-week-low of $4.52. Moreover, at the end of the last trading period, the closing price was at $5.71. JMP Securities initiated coverage on loanDepot Inc (NYSE:LDI) with an Outperform rating. The price target for loanDepot is set to $25.00. The stock has a 52-week-high of $39.85 and a 52-week-low of $14.00. At the end of the last trading period, loanDepot closed at $19.14. JP Morgan initiated coverage on Talis Biomedical Corp (NASDAQ:TLIS) with an Overweight rating. The price target for Talis Biomedical is set to $18.00. The current stock performance of Talis Biomedical shows a 52-week-high of $33.90 and a 52-week-low of $12.60. Moreover, at the end of the last trading period, the closing price was at $12.85. Cowen & Co. initiated coverage on Romeo Power Inc (NYSE:RMO) with an Outperform rating. The price target for Romeo Power is set to $18.00. The stock has a 52-week-high of $32.73 and a 52-week-low of $8.42. At the end of the last trading period, Romeo Power closed at $9.38. Cowen & Co. initiated coverage on QuantumScape Corp (NYSE:QS) with an Outperform rating. The price target for QuantumScape is set to $57.00. Interestingly, in the fourth quarter, QuantumScape's EPS was $2.41. At the moment, the stock has a 52-week-high of $132.73 and a 52-week-low of $28.63. QuantumScape closed at $46.91 at the end of the last trading period. Cowen & Co. initiated coverage on Beam Global (NASDAQ:BEEM) with a Market Perform rating. The price target for Beam Global is set to $33.00. For the third quarter, Beam Global had an EPS of $0.17, compared to year-ago quarter EPS of $0.12. The current stock performance of Beam Global shows a 52-week-high of $75.90 and a 52-week-low of $10.53. Moreover, at the end of the last trading period, the closing price was at $32.64. With an Outperform rating, Cowen & Co. initiated coverage on ChargePoint Holdings Inc (NYSE:CHPT). The price target seems to have been set at $43.00 for ChargePoint Holdings. At the moment, the stock has a 52-week-high of $33.35 and a 52-week-low of $19.50. ChargePoint Holdings closed at $25.58 at the end of the last trading period. Cowen & Co. initiated coverage on Blink Charging Co (NASDAQ:BLNK) with an Outperform rating. The price target for Blink Charging is set to $38.00. For the third quarter, Blink Charging had an EPS of $0.12, compared to year-ago quarter EPS of $0.10. The current stock performance of Blink Charging shows a 52-week-high of $64.50 and a 52-week-low of $1.25. Moreover, at the end of the last trading period, the closing price was at $28.62. BMO Capital initiated coverage on Decibel Therapeutics Inc (NASDAQ:DBTX) with an Outperform rating. The price target for Decibel Therapeutics is set to $30.00. The stock has a 52-week-high of $24.39 and a 52-week-low of $12.75. At the end of the last trading period, Decibel Therapeutics closed at $13.26. With a Neutral rating, B of A Securities initiated coverage on Talis Biomedical Corp (NASDAQ:TLIS). The price target seems to have been set at $14.00 for Talis Biomedical. At the moment, the stock has a 52-week-high of $33.90 and a 52-week-low of $12.60. Talis Biomedical closed at $12.85 at the end of the last trading period. With an Underperform rating, B of A Securities initiated coverage on Lemonade Inc (NYSE:LMND). The price target seems to have been set at $29.00 for Lemonade. In the fourth quarter, Lemonade showed an EPS of $0.60, compared to $2.90 from the year-ago quarter. The stock has a 52-week-high of $188.30 and a 52-week-low of $44.11. At the end of the last trading period, Lemonade closed at $86.79. B of A Securities initiated coverage on Root Inc (NASDAQ:ROOT) with an Underperform rating. The price target for Root is set to $9.00. Interestingly, in the fourth quarter, Root's EPS was $0.72. The stock has a 52-week-high of $25.63 and a 52-week-low of $11.85. At the end of the last trading period, Root closed at $12.35. With a Neutral rating, Credit Suisse initiated coverage on Clover Health Investments Corp (NASDAQ:CLOV). The price target seems to have been set at $10.00 for Clover Health Investments. In the fourth quarter, Clover Health Investments earned $0.20. At the moment, the stock has a 52-week-high of $17.24 and a 52-week-low of $6.31. Clover Health Investments closed at $7.35 at the end of the last trading period. With an Overweight rating, Piper Sandler initiated coverage on Digi International Inc (NASDAQ:DGII). The price target seems to have been set at $29.00 for Digi International. For the first quarter, Digi International had an EPS of $0.32, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $25.61 and a 52-week-low of $6.18. At the end of the last trading period, Digi International closed at $18.48. Raymond James initiated coverage on ReneSola Ltd (NYSE:SOL) with an Outperform rating. The price target for ReneSola is set to $14.50. In the third quarter, ReneSola showed an EPS of $0.05, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $35.77 and a 52-week-low of $0.85. At the end of the last trading period, ReneSola closed at $9.95. With a Hold rating, Tudor Pickering initiated coverage on Renewable Energy Group Inc (NASDAQ:REGI). The price target seems to have been set at $79.00 for Renewable Energy Gr. In the fourth quarter, Renewable Energy Gr showed an EPS of $0.60, compared to $1.18 from the year-ago quarter. At the moment, the stock has a 52-week-high of $117.00 and a 52-week-low of $16.05. Renewable Energy Gr closed at $74.50 at the end of the last trading period. Stifel initiated coverage on Aemetis Inc (NASDAQ:AMTX) with a Buy rating. The price target for Aemetis is set to $25.00. In the third quarter, Aemetis showed an EPS of $0.59, compared to $0.31 from the year-ago quarter. At the moment, the stock has a 52-week-high of $19.98 and a 52-week-low of $0.37. Aemetis closed at $13.15 at the end of the last trading period. With a Buy rating, Jefferies initiated coverage on Twilio Inc (NYSE:TWLO). The price target seems to have been set at $415.00 for Twilio. For the fourth quarter, Twilio had an EPS of $0.04, compared to year-ago quarter EPS of $0.04. The current stock performance of Twilio shows a 52-week-high of $457.30 and a 52-week-low of $68.06. Moreover, at the end of the last trading period, the closing price was at $320.33. Piper Sandler initiated coverage on Talis Biomedical Corp (NASDAQ:TLIS) with an Overweight rating. The price target for Talis Biomedical is set to $17.00. At the moment, the stock has a 52-week-high of $33.90 and a 52-week-low of $12.60. Talis Biomedical closed at $12.85 at the end of the last trading period. With an Overweight rating, Barclays initiated coverage on Avrobio Inc (NASDAQ:AVRO). The price target seems to have been set at $23.00 for Avrobio. For the third quarter, Avrobio had an EPS of $1.01, compared to year-ago quarter EPS of $0.57. The stock has a 52-week-high of $23.50 and a 52-week-low of $9.76. At the end of the last trading period, Avrobio closed at $11.46. Barclays initiated coverage on Decibel Therapeutics Inc (NASDAQ:DBTX) with an Overweight rating. The price target for Decibel Therapeutics is set to $30.00. The stock has a 52-week-high of $24.39 and a 52-week-low of $12.75. At the end of the last trading period, Decibel Therapeutics closed at $13.26. With an Overweight rating, Barclays initiated coverage on Solid Biosciences Inc (NASDAQ:SLDB). The price target seems to have been set at $13.00 for Solid Biosciences. Solid Biosciences earned $0.44 in the third quarter, compared to $0.67 in the year-ago quarter. At the moment, the stock has a 52-week-high of $11.58 and a 52-week-low of $1.93. Solid Biosciences closed at $9.52 at the end of the last trading period. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Outlook For United Natural FoodsEarnings Preview for International Money© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Talis Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of its Talis One™ COVID-19 Test
    GlobeNewswire

    Talis Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of its Talis One™ COVID-19 Test

    MENLO PARK, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it has withdrawn its current application pursuing U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Talis One™ COVID-19 test in the CLIA moderate setting, in favor of focusing on its planned EUA application in the CLIA waived setting. In late February, the FDA informed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity to support Talis’s EUA application. Talis intends to initiate its previously planned clinical validation study in a point-of-care environment, with plans to submit an EUA application for the Talis One COVID-19 test in CLIA waived settings early in the second quarter of 2021. The planned clinical validation study was designed with a different comparator assay, which Talis believes will address the FDA’s concerns. “The company’s business priority remains focused on serving health care providers and their patients in the point-of-care setting, where we continue to see the greatest need for high quality testing,” said Brian Coe, Chief Executive Officer of Talis. “Given the recent correspondence from the Agency and its stated prioritization of point-of-care platforms, we feel this course of action offers a faster path to market.” About Talis Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio. Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “focus,” “pursue,” “will,” “intends,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to Talis’ regulatory strategy, including its intention to prioritize an EUA application for its Talis One COVID-19 test in CLIA waived settings and its ability to submit an EUA early in the second quarter of 2021; and Talis’ ability to initiate a new clinical validation study and a limit-of-detection study for its Talis One COVID-19 test in CLIA waived settings, and the timing thereof. These forward-looking statements are based upon the Company’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that the Talis One COVID-19 test that the Company is developing will be granted an EUA by the FDA; risks that the FDA may require additional information or data in connection with the Company’s EUA; risks and uncertainties associated with the costly and time-consuming development and regulatory approval process and the uncertainty of success; and those discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our prospectus dated February 11, 2021, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. Contact:Media & InvestorsEmily Faucetteefaucette@talisbio.com+1.415.595.9407